CRO Does Not Have Same Rights As Sponsor, Court Says In Tossing Semler Suit Against US FDA

Requiring re-do of Semler bioequivalence studies did not violate the CRO's due process rights, court finds; government has sovereign immunity from 'interference with economic advantage' claims.

Courthouse Inscription
Court finds the US FDA did not violate contract research organization's rights by requiring re-do of its bioequivalence studies.

A district court resoundingly rejected Semler Research Center Private Ltd.'s claims that the US Food and Drug Administration violated its rights and harmed its business by requiring a re-do of bioequivalence studies conducted for its pharmaceutical clients.

In a 17 September order, Judge Consuelo Marshall, of the US District Court for the Central District of California,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet